An anonymous director reports

BLACKHAWK GROWTH CORP. PROVIDES CLARIFICATION ON THE ACQUISITION OF HARDENBROOK

Blackhawk Growth Corp.'s 15 million warrants to be issued with an exercise price of 10 cents have a term of two years from closing to exercise. The directors are all shareholders of Hardenbrook. Justin Hanka and Anoosh Manzoori are also directors of Hardenbrook. No finders' fees or commissions were paid in connection with closing of the acquisition.

As a result, the issued share capital will increase from 77,995,593 shares to 147,995,593 shares. Shareholder approval and Canadian Securities Exchange approval is required and a valuation report will be obtained. Hardenbrook has cash and cash equivalents of $800,000 (Australian) plus four portfolio subsidiaries and a strategic investment in CSE-listed MindBio Therapeutics. The acquisition of Hardenbrook will allow Blackhawk to recapitalize its balance sheet and avoid a private placement for the immediate term. Further updates will be provided to shareholders.

This acquisition is not a change of business as it enhances the current operations of the company. It is also not change of control as no shareholder will own more than 20 per cent of the resulting shares.

The board is committed to continuing the existing operations of Blackhawk and at the same time expanding the groups portfolio with companies with rich intellectual property in sectors heath care AI (artificial intelligence), biopharma and agricultural technology. Hardenbrook is progressing all four of its portfolio companies simultaneously toward a spinout and listing and will also review the existing investments in Blackhawk to advance its commercialization and listing opportunity.

About Blackhawk Growth Corp.

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high-growth companies.

We seek Safe Harbor.